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In a short review of our last discussion, I will remind the reader that cystic fibrosis is a complex 
genetic disease affecting many organs, but it is often lung disease that brings the patient to our 
attention.  The natural history of lung disease begins with the production of abnormal mucus (a 
result of the gene mutations associated with this disease).  We refer to a vicious cycle of disease, 
including early and persistent infection of the airway, concomitant inflammatory response, and, 
over time, progressive airway obstruction.  These processes ultimately result in respiratory 
failure.  As disease worsens there is an increased likelihood of respiratory complications.  In 
addition, patients with cystic fibrosis often present with multiple manifestations of disease upon 
presentation to the hospital, complicating assessment and management.  This second installment 
of recommendations for the hospitalist will briefly address these complications to assist in the 
management of these patients. 
The cystic fibrosis care team often acts as the gate keeper for hospital admissions given the 
specialized ability to recognize a pulmonary exacerbation.  However, patients may present to the 
emergency department with symptoms requiring urgent attention, such as massive hemoptysis or 
pneumothorax.  The following recommendations are summarized from guidelines provided by 
the Cystic Fibrosis Pulmonary Therapies Committee. The CF Foundation pulmonary therapies 
committee consists of a multi-disciplinary group including representative physicians, nurses, 
respiratory therapists, physical therapists, pharmacists, CF families and CF Foundation 
staff.  High volume cystic fibrosis centers participated in a questionnaire, a literature search was 
performed, and an expert panel reviewed all of the data collected.  This information was brought 
to the committee for review with eventual creation of these guidelines following group 
consensus. 
Hemoptysis: 
Hemoptysis is a common symptom in patients with CF; therefore it is important for care 
providers to inquire about bleeding in the outpatient setting.  The literature indicates that about 
9% of patients report hemoptysis , which the author estimates to be the average at this center as 
well. Often there is scant-to-moderate bleeding, described as streaks or spots in the 
sputum.  However, on occasion the patient will describe a large volume of blood.  It is known 
that massive, life-threatening bleeding can occur.  The literature indicates 4% of all patients with 
cystic fibrosis will suffer a massive hemoptysis during his or her lifetime.  Frequently patients 
have difficulty in defining the volume of blood.  The author is able to recall only one patient with 
an accurate measurement.  While driving his car, he reported an episode of hemoptysis where he 
coughed up blood into his coffee cup and filled it to approximately 8 ounces.  However, patients 
often expectorate into the sink or the toilet making volume estimation difficult. The patient may 
overestimate volume, particularly if it is his or her first episode of hemoptysis.  Based on volume 
of expectorate, other symptoms, and circumstances surrounding the hemoptysis, we elect either 
to monitor or treat.  We have asked our patients to contact us with (1) The first episode of 
hemoptysis, and (2) Expectorated blood greater than a teaspoon with or without changes in 
pulmonary symptoms. 
We also would recommend treatment if patient has other pulmonary symptoms with ongoing 
small-volume hemoptysis (greater than 5 ml, but less than 50 ml).  Treatment may consist of oral 
antibiotics at home but may also require an admission to hospital.  We prefer to observe and 
evaluate patients with hemoptysis of 50-250 mL, even if they do not have other pulmonary 
symptoms. 
The patient with massive hemoptysis should always be admitted to the hospital.  This can be life- 
threatening. 
Admission recommendations include: 
1. Discontinue any NSAIDs; 
2. Hold nebulized hypertonic saline; 
3. Administer vitamin K to correct possible deficiency (recall that CF patients often 
experience malabsorption of fat soluble vitamins); 
4. Treatment for pulmonary bacterial colonization in patients with changes in 
sputum, increased cough, or other symptoms suggestive of a pulmonary 
exacerbation. Recall Pseudomonal infection is treated with two anti-pseudomonal 
medications (with a consult to the cystic fibrosis team); 
5. Continue airway clearance including chest physiotherapy with vest, 
bronchodilators, Pulmozyme, and/or inhaled antibiotics. We recognize that mucus 
plugging and the resulting inflammation of the airway is likely the etiology of the 
bleeding; therefore we will need to address this.  However, we may hold IPV and 
if bleeding continues or increases, consider holding Pulmozyme first and then 
other modalities for short time until bleeding subsides; 
6. In the case of massive hemoptysis, we like to alert the bronchoscopy lab, 
Intensive Care Unit, and Interventional Radiology in case of acute 
decompensation. In addition, therapies that should be withheld include BiPAP, 
airway clearance therapies, all other inhaled medications, and NSAIDs. Vitamin 
K should still be administered. Pulmonary function testing should be held until 
significant bleeding has subsided. 
Pneumothorax: 
According to the literature, the average and annual incidence of pneumothorax is 0.64% or one 
in 167 patients per year.  Along with hemoptysis, pneumothorax occurs more commonly in older 
patients with advanced disease.  The author can recall only one pneumothorax in the past eight 
years of practice, occurring in a patient just before the time of her transplant who suffered 
pneumothorax while traveling to Denver by airplane. 
1. Patients with a large pneumothorax should be admitted to the hospital, but those 
with small pneumothoraces who are clinically stable may be closely observed in 
an outpatient setting. 
2. The patient with large pneumothorax should have a chest tube placed. 
3. The patient with first pneumothorax should not go undergo pleurodesis. However 
patients with recurrent large pneumothoraces should undergo pleurodesis to 
prevent recurrence.  The preferred method is surgical pleurodesis. 
4. Since pneumothoraces typically occur in patients with advanced obstructive 
airways disease, one could argue for treatment with antibiotics: however, there is 
no consensus on this issue. 
5. BiPAP should be withheld from patients with pneumothorax as long as the 
pneumothorax is present. 
6. The patient with pneumothorax should not fly in a plane, not lift weights, and 
should not perform spirometry for 2 weeks after the pneumothorax has resolved. 
7. Mechanical airway clearance methods such as Intrapulmonary Percussive 
Ventilation and Positive Expiratory Pressure (PEP) should be held in large 
pneumothorax, but there is no consensus on withholding vest or CPT. 
8. Inhaled airway treatments should NOT be held unless cough is more severe with 
them. 
GI spectrum of Constipation-Obstipation-DIOS (Distal Intestinal Obstructive Syndrome): 
Complete or incomplete intestinal obstruction occurs when there is accumulation of viscous fecal 
material combined with sticky mucoid intestinal content, which adheres to the intestinal wall of 
the terminal ileum and proximal colon.  DIOS is another common complication in cystic 
fibrosis.  A significant mass of material may be interwoven and connected to the crypts and villi 
of the distal intestine and may prove difficult to remove.  In many cases, this is a chronic 
condition that can be aggravated intermittently.   It may occur with a wide range of 
severity.  Some incomplete obstruction cases may go unnoticed by the CF care team when 
patients assume they had a transient “GI bug” that resolved without medical intervention.  Again, 
these complications seem to occur more often in adults than children, more frequently in 
pancreatic-insufficient patients (although occurs in pancreatic sufficient patients as well), and in 
post-transplant patients. 
In constipation, the bowel symptoms and imaging indicate a long-standing condition.   Fecal 
material is distributed throughout the colon.  In DIOS, there is a right lower quadrant mass that 
may be palpable and is also seen on a plain film of the abdomen.  It may present acutely or sub-
acutely with intermittent abdominal pain associated with abdominal distention. 
The phenomenon is again the result of the abnormal gene product CFTR (Cystic fibrosis 
Transmembrane Conductance Regulator).  This is the same chloride channel found in lung 
epithelium, where chloride secretion and sodium absorption are the driving force for fluid 
secretion into the lumen.  In the lung, a non-functional chloride channel causes dehydration of 
the mucus and subsequent plugging of small airways.  In the intestine, abnormalities in the 
mucus also predisposes to obstruction.  In addition, other factors influence the viscosity of 
luminal contents and gut motility.  Inflammatory processes are theorized to contribute to 
neuromuscular dysfunction.  Intestinal wall thickening has been seen involving the muscularis 
mucosa.  Hypertrophy may be the consequence of dysmotility as well as the effect of viscid 
intestinal contents. 
Risk factors for the development of GI problems include dehydration precipitated by illness 
(such as a pulmonary exacerbation), dehydration associated with hot weather, and CF-related 
diabetes which may alter hydration status. 
Treatment for this GI spectrum includes oral rehydration combined with stool products for mild, 
incomplete obstruction or constipation.  Osmotic laxatives, which draw more fluid into the 
intestinal lumen, are the most effective and best tolerated.  Gut lavage with balanced electrolyte 
solutions and intravenous fluids are rarely required.  Care should be taken to avoid rapid fluid 
shifts.  We attempt to avoid dehydration and optimize enzyme dosing to decrease the risk of 
recurrence.  Some patients seem to do better with prophylactic osmotic laxative therapy. 
CF-Related Diabetes (ESRD): 
CFRD is the most common comorbidity in cystic fibrosis and occurs in 40-50% of adults.  The 
disease has features of both type I and type II diabetes mellitus; however it is a clinically distinct 
phenomenon.  The primary cause is insulin insufficiency due to damage to the pancreas. 
However, fluctuating levels of insulin resistance also occur and are related to chronic 
inflammation with acute intermittent illnesses.  Diagnosis is generally not made during acute 
hospitalization for pulmonary exacerbation or other illness but rather during a time of stable 
health. 
Because the main pathology in CFRD is insulin insufficiency, the treatment is insulin.  There is 
clear evidence that patients with insulin therapy who achieve good control of blood sugars also 
demonstrate improvements in weight, protein anabolism, pulmonary function, and survival. 
There is no single proven insulin regimen, and each case requires individualized 
attention.  CFRD patients still produce some endogenous insulin and except during acute illness, 
insulin needs are often low such as the case with type I diabetes in the so-called “honeymoon 
period.”  It is during an acute illness or with oral steroid therapy that insulin requirements may 
steeply rise.  Once the illness resolves, it may take 4-6 weeks for insulin requirements gradually 
to return to baseline. 
The goals of glucose management are the same as ADA recommendations for all patients with 
diabetes.  Hemoglobin A1c values less than 7% are the usual target.  However, hemoglobin A1C 
is often low in cystic fibrosis patients secondary to an increased rate of turnaround in red blood 
cells. 
As you may recall from our first article, meeting nutrition requirements is essential in the 
management of this disease.  Adequate caloric intake to maintain target BMI is critical to health 
and survival in cystic fibrosis patients.  Therefore those patients with CFRD should NOT 
decrease calorie intake.  These patients require a very high calorie diet that is usually 120-150% 
of the recommended daily intake for age.  This is because there is increased resting energy 
expenditure with increased work of breathing and there is increased loss of calories through 
malabsorption. 
CF evidence-based guidelines also recommend exercise for its benefit to overall health, 
cardiovascular fitness, and pulmonary clearance.  Virtually all cystic fibrosis patients, even those 
with severe pulmonary disease, are capable of participating in strength training and aerobic 
exercise. 
Cystic Fibrosis “Pearls “ 
– Cystic fibrosis is a progressive genetic disease, marked by episodes of pulmonary exacerbation 
– Treatments are based on pathophysiology 
– Airway clearance, nutrition, and antibiotics are key elements to manage in treatment 
– A patient’s “usual” or home oral antibiotics are NOT stopped upon presentation to hospital for 
intravenous antibiotics 
– Examples of treatments to promote airway clearance include bronchodilators, mucolytic 
agents, mucus hydration agents, inhaled antibiotics and mechanical clearance (vest, IPV, 
accapella, coronette, aerobika etc) 
– Give CF patients vitamin K for hemoptysis 
– Think about airway effects when considering treatments for patients with both hemoptysis and 
pneumothorax 
– Antibiotics should be considered whenever there is a change in pulmonary symptoms; 
Pseudomonas is treated with two agents with different mechanisms of action 
– Most cystic fibrosis patients have some degree of constipation and bowel management is 
always with osmotic agents 
– Do not put CFRD patients on a calorie restricted diet 
– Do not put CF patients on a salt-restricted diet 
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